DOI: 10.1080/17425247.2018.1444601
关键词:
摘要: ABSTRACTIntroduction: The development of therapeutics for central nervous system (CNS) disorders is still considered a challenging area in drug due to insufficient translocation through the blood-brain barrier (BBB). Under normal conditions, BBB restrict penetration more than 98% blood-borne molecules including drugs CNS. However, recent research findings have proven that nature altered several neurological conditions. This complexity encourages revisiting delivery strategies CNS as this can give wide range opportunities development.Areas covered: review focuses on nanotechnology-based platforms designed selective recruitment into lesioned brain by taking advantages disruption associated with certain conditions.Expert opinion: Current therapeutic do not fully address pathophysiological adaptation their design. lack ...